Physician profile
James J Davidson
NPI 1720067762
$19,641.73
in general payments reported to CMS, 2019-2025
29 companies · $3,718 in 2025
The $3,718 reported for 2025 was more than what 79% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,231 · 2020: $1,623 · 2021: $312 · 2022: $3,020 · 2023: $2,345 · 2024: $3,393 · 2025: $3,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,275 · Food and Beverage: $4,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,275.29 |
| Food and Beverage | $4,180.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $7,050.23 | 2019-2024 | |
| Zimmer Biomet Holdings, INC. | $3,672.45 | 2019-2025 | Persona, Mymobility Platform, Rosa |
| Medical Device Business Services, INC. | $2,242.06 | 2019-2020 | |
| Rock Medical Orthopedics, INC. | $1,790.09 | 2020-2024 | |
| Sonex Health, INC. | $1,618.51 | 2024 | Sx-One Microknife |
| Cdc Medical LLC | $1,503.31 | 2019 | |
| Depuy Synthes Sales INC. | $435.57 | 2019-2025 | Vapr, Dynacord |
| E.R. Squibb & Sons, L.L.C. | $224.56 | 2022-2024 | Opdivo, Reblozyl |
| Medtronic, INC. | $137.40 | 2025 | Unid_pass |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | Ultomiris |
| Ars Pharmaceuticals Operations, INC. | $103.15 | 2025 | Neffy |
| Orthofix Medical, INC. | $98.41 | 2024-2025 | Physio-Stim |
| Dexcom, INC. | $95.00 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Smith+Nephew, INC. | $75.16 | 2019-2025 | Renasys Go V2 Home |
| Bioventus LLC | $74.48 | 2019-2025 | Xcell |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.61 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $47.92 | 2020 | |
| Janssen Pharmaceuticals, INC | $40.00 | 2019 | |
| Stryker Corporation | $37.58 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.50 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $35.00 | 2023 | Inpefa |
| Pfizer INC. | $35.00 | 2025 | |
| Portola Pharmaceuticals, LLC | $23.84 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $16.90 | 2025 | |
| Ferring Pharmaceuticals INC. | $16.09 | 2020 | |
| Paragon 28, INC. | $15.73 | 2019 | |
| Catalyst Orthoscience | $15.58 | 2021 | |
| Novo Nordisk INC | $14.47 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.